Dr Louise Kostos
Clinical (Lecturer)
The Sir Peter MacCallum Department of Oncology
29 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies
DOI: 10.2967/jnumed.126.2720852026
Journal article
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
DOI: 10.1016/j.eururo.2025.08.0152026
Journal article
Reply to Tonghu Liu, Congcong Zhu, and Zechen Yan's Letter to the Editor re: Heidi Fettke, Louise Kostos, Maria Docanto, et al. Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.08.015
DOI: 10.1016/j.euf.2025.12.0122026
Journal article
Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial
DOI: 10.1016/j.euf.2026.05.0172025
Journal article
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
DOI: 10.2967/jnumed.125.2708042025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Conference Proceedings
2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
DOI: 10.1016/j.annonc.2025.08.3002
RECENT SCHOLARLY WORKS
2025
Journal article
Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer
DOI: 10.1111/bju.167512025
Journal article
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
DOI: 10.1016/S1470-2045(25)00332-82025
Journal article
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
DOI: 10.2967/jnumed.124.268640